

# Cataract - Pipeline Review, H1 2020

<https://marketpublishers.com/r/C034B72858DEN.html>

Date: April 2020

Pages: 40

Price: US\$ 2,000.00 (Single User License)

ID: C034B72858DEN

## Abstracts

Cataract - Pipeline Review, H1 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cataract - Pipeline Review, H1 2020, provides an overview of the Cataract (Ophthalmology) pipeline landscape.

Cataract is a clouding of the normally clear lens of eye that affects vision. Symptoms include clouded, blurred or dim vision, increasing difficulty with vision at night, fading or yellowing of colors, double vision in a single eye and frequent prescription changes in eye wear. Risk factors include age, diabetes, drinking excessive amounts of alcohol, high blood pressure, obesity and smoking.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cataract - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Cataract (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cataract (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Cataract and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Preclinical

and Discovery stages are 7 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Cataract (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Cataract (Ophthalmology).

The pipeline guide reviews pipeline therapeutics for Cataract (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Cataract (Ophthalmology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Cataract (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline

projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Cataract (Ophthalmology)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Cataract (Ophthalmology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Cataract (Ophthalmology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

- Introduction
- Global Markets Direct Report Coverage
- Cataract - Overview
- Cataract - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Cataract - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Cataract - Companies Involved in Therapeutics Development
- Calpain Therapeutics Pty Ltd
- Cellix Bio Pvt Ltd
- CGeneTech (Suzhou China) Co Ltd
- Dhp Korea Ltd
- Genisphere LLC
- Kubota Vision Inc
- Plex Pharmaceuticals Inc
- ViewPoint Therapeutics Inc
- Cataract - Drug Profiles
- CAP-1160 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- CAT-811 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- CGT-1507 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- CLXOPH-65 - Drug Profile

Product Description  
Mechanism Of Action  
R&D Progress  
DHPNP-06 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
GL-249 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
Small Molecule for Presbyopia and Cataract - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
Small Molecule to Inhibit NFkB for Ophthalmology, Oncology, Dermatology,  
Immunology and Infectious Disease - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
VP-1001 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
Cataract - Dormant Projects  
Cataract - Discontinued Products  
Cataract - Product Development Milestones  
Featured News & Press Releases  
May 01, 2018: ViewPoint Appoints Dr. Robert Kim as Chief Medical Officer  
Sep 07, 2016: Plex Pharmaceuticals awarded \$299,173 NIH Phase I SBIR grant  
funding to find non-surgical treatments for Cataracts  
May 13, 2012: Calpain Therapeutics Wins Commercialisation Australia Grant To  
Progress Anti-Cataract Programme  
Sep 04, 2011: New Drug Eyes Way To Beat Cataracts  
Appendix  
Methodology  
Coverage  
Secondary Research  
Primary Research

[Expert Panel Validation](#)

[Contact Us](#)

[Disclaimer](#)

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Cataract, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products under Development by Universities/Institutes, H1 2020  
Products under Development by Companies, H1 2020  
Products under Development by Universities/Institutes, H1 2020  
Number of Products by Stage and Target, H1 2020  
Number of Products by Stage and Mechanism of Action, H1 2020  
Number of Products by Stage and Route of Administration, H1 2020  
Number of Products by Stage and Molecule Type, H1 2020  
Cataract - Pipeline by Calpain Therapeutics Pty Ltd, H1 2020  
Cataract - Pipeline by Cellix Bio Pvt Ltd, H1 2020  
Cataract - Pipeline by CGeneTech (Suzhou China) Co Ltd, H1 2020  
Cataract - Pipeline by Dhp Korea Ltd, H1 2020  
Cataract - Pipeline by Genisphere LLC, H1 2020  
Cataract - Pipeline by Kubota Vision Inc, H1 2020  
Cataract - Pipeline by Plex Pharmaceuticals Inc, H1 2020  
Cataract - Pipeline by ViewPoint Therapeutics Inc, H1 2020  
Cataract - Dormant Projects, H1 2020  
Cataract - Discontinued Products, H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Cataract, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products by Targets, H1 2020  
Number of Products by Stage and Targets, H1 2020  
Number of Products by Mechanism of Actions, H1 2020  
Number of Products by Stage and Mechanism of Actions, H1 2020  
Number of Products by Routes of Administration, H1 2020  
Number of Products by Stage and Routes of Administration, H1 2020  
Number of Products by Molecule Types, H1 2020  
Number of Products by Stage and Molecule Type, H1 2020

### COMPANIES MENTIONED

Calpain Therapeutics Pty Ltd  
Cellix Bio Pvt Ltd  
CGeneTech (Suzhou China) Co Ltd  
Dhp Korea Ltd  
Genisphere LLC  
Kubota Vision Inc  
Plex Pharmaceuticals Inc  
ViewPoint Therapeutics Inc



## I would like to order

Product name: Cataract - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/C034B72858DEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C034B72858DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970